BioCryst Historical Cash Flow

BCRX Stock

USD 7.60 0.11 1.47%

Analysis of BioCryst Pharmaceuticals cash flow over time is an excellent tool to project BioCryst Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 5.1 M or Depreciation of 970.6 K as it is a great indicator of BioCryst Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining BioCryst Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioCryst Pharmaceuticals is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

About BioCryst Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in BioCryst balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which BioCryst's non-liquid assets can be easily converted into cash.

BioCryst Pharmaceuticals Cash Flow Chart

At this time, BioCryst Pharmaceuticals' Begin Period Cash Flow is fairly stable compared to the past year. Other Non Cash Items is likely to rise to about 111.9 M in 2024, despite the fact that Change In Cash is likely to grow to (184.1 M).

Begin Period Cash Flow Other Non Cash Items Capital Expenditures End Period Cash Flow Change To Liabilities

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by BioCryst Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of BioCryst Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most accounts from BioCryst Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Begin Period Cash Flow is fairly stable compared to the past year. Other Non Cash Items is likely to rise to about 111.9 M in 2024, despite the fact that Change In Cash is likely to grow to (184.1 M).

	2021	2022	2023	2024 (projected)
Other Non Cash Items	54.2M	98.1M	106.5M	111.9M
Depreciation	777K	1.4M	1.7M	970.6K

Other Non Cash Items Depreciation

BioCryst Pharmaceuticals cash flow statement Correlations

	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Net Income	End Period Cash Flow	Stock Based Compensation	Change To Liabilities	Change To Account Receivables	Sale Purchase Of Stock	Change To Inventory	Investments	Change Receivables	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Netincome	Net Borrowings	Change To Operating Activities	Issuance Of Capital Stock	Exchange Rate Changes
Change In Cash		-0.01	0.8	-0.48	-0.52	-0.62	-0.15	0.31	0.36	-0.32	0.91	0.11	0.18	-0.02	0.53	0.25	-0.27	-0.47	-0.73	0.35	0.37	0.84	0.58
Free Cash Flow	-0.01		0.42	-0.77	-0.63	-0.59	-0.04	0.9	-0.83	-0.1	-0.1	0.51	-0.45	0.65	0.27	0.6	-0.77	-0.57	-0.52	-0.6	0.29	0.27	0.17
Change In Working Capital	0.8	0.42		-0.76	-0.69	-0.79	-0.08	0.59	-0.12	-0.43	0.72	0.47	-0.01	0.33	0.52	0.62	-0.57	-0.71	-0.82	-0.06	0.53	0.9	0.48
Begin Period Cash Flow	-0.48	-0.77	-0.76		0.75	0.93	0.19	-0.91	0.63	0.4	-0.32	-0.55	0.21	-0.67	-0.59	-0.67	0.88	0.9	0.87	0.54	-0.6	-0.76	-0.48
Depreciation	-0.52	-0.63	-0.69	0.75		0.78	-0.08	-0.79	0.36	0.42	-0.52	-0.17	0.2	-0.39	-0.36	-0.4	0.73	0.7	0.8	0.28	-0.46	-0.67	-0.43
Other Non Cash Items	-0.62	-0.59	-0.79	0.93	0.78		0.19	-0.85	0.41	0.48	-0.5	-0.47	0.15	-0.43	-0.48	-0.67	0.9	0.97	0.97	0.46	-0.65	-0.89	-0.74
Capital Expenditures	-0.15	-0.04	-0.08	0.19	-0.08	0.19		-0.11	0.07	0.0	-0.01	-0.35	-0.36	0.02	0.03	-0.25	0.08	0.26	0.17	0.2	0.18	-0.19	-0.16
Net Income	0.31	0.9	0.59	-0.91	-0.79	-0.85	-0.11		-0.68	-0.27	0.19	0.47	-0.41	0.55	0.4	0.65	-0.94	-0.8	-0.82	-0.54	0.44	0.57	0.53
End Period Cash Flow	0.36	-0.83	-0.12	0.63	0.36	0.41	0.07	-0.68		0.13	0.46	-0.5	0.37	-0.75	-0.19	-0.48	0.67	0.52	0.26	0.88	-0.31	-0.06	0.07
Stock Based Compensation	-0.32	-0.1	-0.43	0.4	0.42	0.48	0.0	-0.27	0.13		-0.24	0.1	-0.11	-0.49	-0.16	-0.04	0.43	0.48	0.48	0.23	-0.4	-0.45	-0.38
Change To Liabilities	0.91	-0.1	0.72	-0.32	-0.52	-0.5	-0.01	0.19	0.46	-0.24		-0.11	0.28	-0.16	0.36	0.08	-0.18	-0.37	-0.61	0.41	0.22	0.72	0.52
Change To Account Receivables	0.11	0.51	0.47	-0.55	-0.17	-0.47	-0.35	0.47	-0.5	0.1	-0.11		-0.28	0.19	0.19	0.93	-0.46	-0.53	-0.38	-0.46	0.38	0.45	0.14
Sale Purchase Of Stock	0.18	-0.45	-0.01	0.21	0.2	0.15	-0.36	-0.41	0.37	-0.11	0.28	-0.28		-0.14	-0.37	-0.37	0.39	0.09	0.16	0.13	0.08	0.04	-0.05
Change To Inventory	-0.02	0.65	0.33	-0.67	-0.39	-0.43	0.02	0.55	-0.75	-0.49	-0.16	0.19	-0.14		0.49	0.17	-0.52	-0.45	-0.33	-0.57	0.39	0.19	-0.09
Investments	0.53	0.27	0.52	-0.59	-0.36	-0.48	0.03	0.4	-0.19	-0.16	0.36	0.19	-0.37	0.49		0.21	-0.34	-0.39	-0.5	0.01	0.25	0.51	0.13
Change Receivables	0.25	0.6	0.62	-0.67	-0.4	-0.67	-0.25	0.65	-0.48	-0.04	0.08	0.93	-0.37	0.17	0.21		-0.67	-0.7	-0.61	-0.46	0.44	0.61	0.4
Cash And Cash Equivalents Changes	-0.27	-0.77	-0.57	0.88	0.73	0.9	0.08	-0.94	0.67	0.43	-0.18	-0.46	0.39	-0.52	-0.34	-0.67		0.9	0.85	0.63	-0.5	-0.62	-0.63
Cash Flows Other Operating	-0.47	-0.57	-0.71	0.9	0.7	0.97	0.26	-0.8	0.52	0.48	-0.37	-0.53	0.09	-0.45	-0.39	-0.7	0.9		0.89	0.62	-0.66	-0.83	-0.68
Change To Netincome	-0.73	-0.52	-0.82	0.87	0.8	0.97	0.17	-0.82	0.26	0.48	-0.61	-0.38	0.16	-0.33	-0.5	-0.61	0.85	0.89		0.26	-0.56	-0.9	-0.79
Net Borrowings	0.35	-0.6	-0.06	0.54	0.28	0.46	0.2	-0.54	0.88	0.23	0.41	-0.46	0.13	-0.57	0.01	-0.46	0.63	0.62	0.26		-0.46	-0.15	-0.11
Change To Operating Activities	0.37	0.29	0.53	-0.6	-0.46	-0.65	0.18	0.44	-0.31	-0.4	0.22	0.38	0.08	0.39	0.25	0.44	-0.5	-0.66	-0.56	-0.46		0.66	0.38
Issuance Of Capital Stock	0.84	0.27	0.9	-0.76	-0.67	-0.89	-0.19	0.57	-0.06	-0.45	0.72	0.45	0.04	0.19	0.51	0.61	-0.62	-0.83	-0.9	-0.15	0.66		0.68
Exchange Rate Changes	0.58	0.17	0.48	-0.48	-0.43	-0.74	-0.16	0.53	0.07	-0.38	0.52	0.14	-0.05	-0.09	0.13	0.4	-0.63	-0.68	-0.79	-0.11	0.38	0.68

Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change In Cash	87.4M	158.6M	233.4M	(201.5M)	(193.8M)	(184.1M)
Free Cash Flow	(89.9M)	(137.7M)	(144.5M)	(163.2M)	(97.3M)	(92.4M)
Change In Working Capital	(872K)	26.9M	8.1M	(58.9M)	(32.4M)	(30.8M)
Begin Period Cash Flow	28.3M	115.7M	274.3M	507.7M	306.2M	321.6M
Other Cashflows From Financing Activities	60.1M	142.0M	15.7M	14.8M	5.3M	5.1M
Depreciation	724K	748K	777K	1.4M	1.7M	970.6K
Other Non Cash Items	1.3M	2.4M	54.2M	98.1M	106.5M	111.9M
Capital Expenditures	343K	514K	2.4M	1.4M	2.2M	2.1M
Total Cash From Operating Activities	(89.6M)	(137.2M)	(142.2M)	(161.9M)	(95.1M)	(90.4M)
Net Income	(108.9M)	(182.8M)	(184.1M)	(247.1M)	(226.5M)	(215.2M)
Total Cash From Financing Activities	99.1M	302.7M	359.7M	88.0M	32.5M	57.9M
End Period Cash Flow	115.7M	274.3M	507.7M	306.2M	112.4M	66.1M
Stock Based Compensation	17.7M	14.8M	34.6M	44.7M	55.6M	52.8M
Total Cashflows From Investing Activities	77.9M	(6.9M)	15.8M	(128.2M)	(115.4M)	(109.6M)
Change To Liabilities	14.8M	24.1M	40.7M	(22.5M)	(25.8M)	(24.5M)
Change To Account Receivables	(16.2M)	18.5M	(23.8M)	(21.5M)	(6.1M)	(6.4M)
Sale Purchase Of Stock	56.3M	79.6M	110.5M	65.8M	75.7M	51.5M
Change To Inventory	1.6M	(7.0M)	(8.8M)	(12.4M)	(1.5M)	(1.5M)
Investments	78.3M	(6.3M)	18.2M	(128.2M)	(25.8M)	(24.5M)
Change Receivables	1.8M	(17.9M)	13.9M	(20.8M)	(18.7M)	(17.8M)
Cash And Cash Equivalents Changes	(25.3M)	87.4M	158.6M	233.4M	268.4M	281.8M
Cash Flows Other Operating	(7.8M)	652K	(4.0M)	48.3M	55.6M	58.4M
Change To Netincome	18.1M	15.4M	33.0M	141.8M	163.1M	171.3M
Net Borrowings	19.5M	67.4M	293.9M	73.1M	84.0M	64.6M
Change To Operating Activities	1.7M	4.6M	(3.0M)	(2.6M)	(2.3M)	(2.2M)
Issuance Of Capital Stock	58.5M	93.3M	50M	190K	342K	324.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioCryst Historical Cash Flow

About BioCryst Cash Flow Analysis

BioCryst Pharmaceuticals Cash Flow Chart

Begin Period Cash Flow

Capital Expenditures

BioCryst Pharmaceuticals cash flow statement Correlations

BioCryst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioCryst Pharmaceuticals cash flow statement Accounts

Also Currently Popular

Additional Tools for BioCryst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash Flows Other Operating	+ 0.97	Other Non Cash Items
Change To Netincome	+ 0.97	Other Non Cash Items
Other Non Cash Items	+ 0.93	Begin Period Cash Flow
Change Receivables	+ 0.93	Change To Account Receivables
Change To Liabilities	+ 0.91	Change In Cash
Net Income	+ 0.9	Free Cash Flow

Cash And Cash Equivalents Changes	- 0.94	Net Income
Net Income	- 0.91	Begin Period Cash Flow
Issuance Of Capital Stock	- 0.9	Change To Netincome
Issuance Of Capital Stock	- 0.89	Other Non Cash Items
Net Income	- 0.85	Other Non Cash Items
Issuance Of Capital Stock	- 0.83	Cash Flows Other Operating